

## PRESS RELEASE

### TAKEOVER BID PROMOTED BY FINE FOODS & PHARMACEUTICALS N.T.M. S.P.A. ON THE EURO COSMETIC S.P.A. ORDINARY SHARES

**Bid Subscription Period closes**

**Bid provisional results**

**More than 99 per cent achieved**

Verdellino (BG), 17 December 2021

Fine Foods & Pharmaceuticals N.T.M. S.p.A. ("**Fine Foods**") announces that on 17 December 2021, 5:30 pm, the subscription period (the "**Subscription Period**") of the takeover bid under Articles 102 et seq. of the TUF - Consolidated Law on Finance, which is mandatory under Article 6 of the Euro Cosmetic S.p.A. Articles of Association (the "**Bid**"), has closed. The Bid was promoted by Fine Foods for up to 1,187,600 ordinary shares (the "**Shares**") of Euro Cosmetic S.p.A. ("**Euro Cosmetic**" or the "**Issuer**").

Terms used with a capital letter in this press release, unless otherwise defined, follow the Bid document meanings for the Bid approved by CONSOB with resolution no. 22089 of 24 November 2021 and published on 26 November 2021 (the "**Bid Document**").

Based on provisional results reported by Società per Amministrazioni Fiduciarie "SPAFID" S.p.A., which is the Intermediary In Charge of Coordinating the Collection of Subscriptions, at the end of the Subscription Period, 1,008,000 Shares, representing approximately 21.169% of the Issuer's share capital, have been tendered. Considering that (i) as of the Bid Document date, the Bidder held 3,574,000 Euro Cosmetic's ordinary shares representing approximately 75.06% of the Issuer's share capital, and (ii) during the Subscription Period (including today's date), the Bidder has acquired a further 150,800 Shares outside the Bid, representing approximately 3.167% of the Issuer's share capital as seen in the press releases under article 41, paragraph 2, letter c) of the Issuers' Regulations, based on the provisional results, on the payment date, the Bidder will hold 4,732,800 Issuer's ordinary shares, equal to 99.395% of the capital.

The price of €8.60 for each Bid-tendered Share, shall be paid to the shareholders subscribing to the Bid during the Subscription Period on 22 December 2021.

Given the above, the Bidder announces that: (i) the Tender Reopening Period will not take place, under Article 40-bis, paragraph 3, letter b) of the Issuers' Regulations; and (ii) based on the Bid provisional results, as the Bidder has come to hold more than 95% of the Issuer's share capital, the requirements for the fulfilment of the Sell-out under article 108, paragraph 1, of the TUF have been met.

Following the confirmation of the results, as stated in the Bid Document, the Bidder shall exercise the Squeeze-out on the remaining maximum 28,800 Shares, equal to approximately 0.605% of the Issuer's share capital (the "**Remaining Shares**"). By exercising the Squeeze-out, the Bidder will fulfil the Sell-out under Article 108, paragraph 1, of the TUF in a Joint Procedure.

---

Fine Foods & Pharmaceuticals N.T.M. S.p.A.

Further information on the Joint Procedure will be disclosed in a press release on the Bid results which will be disseminated by the Bidder under Article 41, paragraph 6, of the Issuers' Regulations.

\*\*\*

This press release is available on the Fine Foods website [www.finefoods.it](http://www.finefoods.it), in the Investor Relations/Press Releases section and in the Investor relations / Takeover Bid section.

\*\*\*

Fine Foods & Pharmaceuticals N.T.M. S.p.A., listed on Euronext STAR Milan, is an Italian independent Contract Development & Manufacturing Organisation (CDMO). It develops and manufactures contract products for the pharmaceutical and nutraceutical industries. Fine Foods is also active in the cosmetics, biocides and medical devices industries with its acquisition of Pharmatek-PMC and the most recent Euro Cosmetic acquisition. Founded in 1984, from a pharmaceutical and nutraceutical synergy, its main objective is to research and develop quality and innovation on behalf of its customers. With € 172 million revenue in 2020 and an 11 per cent CAGR over the last decade, it is a growing and future-oriented company. The sustainability of the business model and the holistic approach to ESG, together with product innovation, are drivers that will allow the company to fully develop its intrinsic potential.

\*\*\*

For information:

**Fine Foods & Pharmaceuticals N.T.M. S.p.A.**  
*Investor Relations*  
tel. +39 035 4821382  
[ir@finefoods.it](mailto:ir@finefoods.it)

**CDR Communication**  
*Media Relations*  
Marianna Tremolada  
[marianna.tremolada@cdr-communication.it](mailto:marianna.tremolada@cdr-communication.it)